suchasforCOVID-19.
recombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarg
reactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityof
eggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadv
antibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsenc
certainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotec
structuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexp
recombinantproteins,uniquepost-translationalprocessingoftherHAininsectcellsinstillsfavourabletertiaryandquaternary
toconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristic
studiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompa
systemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbee
vaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionve
improvethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgenerat
Theinfluenzavaccine fieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,and flexibilityofmanufacturing,an